Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates
“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.
Dr. Moran credits the baby boomer generation with this awareness in action. Whether it’s through social media or simply talking to a friend, patients are being introduced to brachytherapy through channels that weren’t available 10 years ago. Dr. Moran hopes to use these new channels to share patients’ stories and testimonials.
The more widely those stories are shared, the greater the opportunity for more men to take an active role in their treatment and reaching optimal quality of life thereafter.
That said, Dr. Moran notes that the internet is not always a reliable source and that he hopes to always provide patients with the most accurate and valuable information when making their treatment decision.
If you would like to learn more about how brachytherapy improves outcomes for many types of cancer patients, especially prostate cancer patients, contact firstname.lastname@example.org.
Isoray To Launch The Power of Blu Introducing A New Brand Identity at the American Brachytherapy Society’s Annual Meeting
New Brand Identity to Be Unveiled Thursday, June 13 RICHLAND, WASHINGTON – June 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced...
Record Revenue and Gross Profit Revenue Increased 22% Year-Over-Year RICHLAND, WASHINGTON – May 9, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...
Conference Call is May 9 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – May 1, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it...
Patients and Families
The Isoray team is here to help. Contact us below and our experts will help connect you with clinicians, researchers, and our support team to answer your questions about Isoray and Cesium-131.